Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Acepodia logo — POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER

Acepodia

POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER

Founded 2016 United States Alameda, United States 49 employees Series D Total: $256.00M Biotechnology, Health Care +1

General Information

Company Name Acepodia
Founded Year 2016
Location United States Alameda, United States
Founders / Decision Makers
Team member
Employees 49
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Acepodia. To contact Acepodia, visit acepodia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Acepodia compare?

A PDF of Acepodia and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Acepodia soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Acepodia

Acepodia is a clinical-stage biotechnology company founded in 2016, with a focus on developing innovative and highly effective cell therapies for cancer patients. The company's slogan, "POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER," encapsulates its mission. Acepodia leverages its Antibody-Cell Conjugation (ACC) technology to link tumor-targeting antibodies to its proprietary immune effector cells, creating novel antibody cell effector (ACE) therapies. These therapies demonstrate increased binding strength against tumors expressing low levels of tumor antigens, promising a broad impact. The last Series D investment of $100.00M on 06 June 2023 was secured from Digital Mobile Venture. The company's headquarters are based in the United States. Acepodia is backed by a team of seasoned leadership and scientific experts committed to advancing its robust pipeline of off-the-shelf ACE therapies, holding great potential to benefit a wide population of patients across various solid tumors and hematologic cancers.

Business keywords: Acepodia, clinical-stage, cancer cell immunotherapy, off-the-shelf, NK cells, antibody-cell conjugation, cell therapy, oncology, immune effector cells, solid tumors, hematologic cancers, immunotherapeutic strategies, interdisciplinary technology

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $100.00M 1
Digital Mobile Venture
06 Jun 2023
Series C $109.00M 1
Digital Mobile Venture
02 Dec 2021
Series B $47.00M 4
8VC CDIB Capital Defta Partners
8VC, CDIB Capital +2
16 Mar 2021

Acepodia Alternatives & Competitors

View All Alternatives
Acepodia vs
Adicet Bio, Inc
Adicet Bio, Inc United States

A biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell...

IPO
124 employees
Biopharma, Biotechnology
Compare Acepodia vs Adicet Bio, Inc
Acepodia vs
Compass Therapeutics Inc.
Compass Therapeutics Inc. United States

We are developing next-generation antibodies into transformative cancer therapies that improve patie...

IPO
57 employees
Biopharma, Biotechnology
Compare Acepodia vs Compass Therapeutics Inc.
Acepodia vs
ONK Therapeutics
ONK Therapeutics Ireland

Pioneering optimally engineered NK cell therapies to cure patients with cancer.

Series A
20 employees
Biotechnology, Health Care
Also compare with: Acepodia vs Abcuro, Inc Abcuro, Inc View all alternatives

FAQ About Acepodia

POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER
Acepodia was founded in 2016.
Acepodia is headquartered in Alameda, United States.
Acepodia operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Acepodia, clinical-stage, cancer cell immunotherapy and off-the-shelf.
Acepodia has approximately 49 employees.
Acepodia has completed 3 funding rounds, raising a total of $256.00M. The latest funding stage is Series D.
Top alternatives and competitors to Acepodia include Adicet Bio, Inc, Compass Therapeutics Inc., ONK Therapeutics, Revitope, Abcuro, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Acepodia and Adicet Bio, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Acepodia, https://bouncewatch.com/company/acepodia, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout